bioRxiv Preprint Server
January 22, 2020
Greer McKendrick, Hannah Garrett, Holly E. Jones et al.
1 citation
preprint
Patients suffering from opioid use disorder often relapse during periods of abstinence, which is posited to be caused by negative affective states that drive motivated behaviors. Here, we explored whether conditioning mice with morphine in a CPP training paradigm evoked anxietylike behavior during morphine abstinence. To do this, mice were conditioned with morphine (10 mg/kg, i.p.) for five...
Indian Journal of Psychological Medicine
January 17, 2020
C S Gautam, Sonia S Mahajan, Jatin Sharma et al.
31 citations
Ketamine is a noncompetitive antagonist of the N-methyl-D-aspartate (NMDA) receptor which also interacts with various other receptors that account for its myriad actions. Originally approved as a general anesthetic, it is being explored to be repurposed for numerous other indications such as depressive disorders, suicidal ideation, substance-use disorders, anxiety disorders, chronic pain,...
Proceedings of the National Academy of Sciences
January 15, 2020
Matthew E. Klein, Joshua Chandra, Salma A. Sheriff et al.
157 citations
Significance Ketamine, an NMDA receptor antagonist, has generated intense excitement as a therapy for treatment-resistant depression. However, ketamine and its metabolites can act on a wide range of targets, including opioid receptors, which has raised concerns. Using behavioral and cellular assays in rodents, we find that blocking opioid function prevents the antidepressant-like effects of...
Our Love Affair with Drugs
January 10, 2020
J. Winter
We will consider just two drugs in this chapter. They are phencyclidine and ketamine. Both are widely used as anesthetic agents, ketamine in humans and phencyclidine in animals. The acronym for phencyclidine that we will use, PCP, comes from its chemical name 1-(1-PhenylCyclohexyl)-Piperidine. In addition to their medical use, both ketamine and PCP have gained roles as recreational drugs or, as...
The Journal of ECT
January 6, 2020
Qibin Chen, Jun Dong, Jie Luo et al.
22 citations
OBJECTIVES It remains controversial whether a subanesthetic dose of ketamine could modulate the antidepressant effect of electroconvulsive therapy (ECT) in patients with major depressive disorder. We investigated the effect of ketamine on accelerating the antidepressant efficacy of ECT. METHODS One hundred twenty-seven patients with major depressive disorder were included in this randomized,...
Progress in Neuro-Psychopharmacology and Biological Psychiatry
2020
Stefania Schiavone, M. Morgese, M. Bove et al.
Administration in adulthood of subanaesthetic doses of ketamine, an NMDA receptor (NMDA-R) antagonist, is commonly used to induce psychotic-like alterations in rodents. The NADPH oxidase (NOX) derived-oxidative stress has been shown to be implicated in ketamine-induced neurochemical dysfunctions and in the loss of parvalbumin (PV)-positive interneurons associated to the administration of this...
Biological Psychiatry: Cognitive Neuroscience and Neuroimaging
January 2020
Rachael Sumner, Rebecca McMillan, Meg J. Spriggs et al.
The rapid-acting clinical effects of ketamine as a novel treatment for depression along with its complex pharmacology have made it a growing research area. One of the key mechanistic hypotheses for how ketamine works to alleviate depression is by enhancing long-term potentiation (LTP)-mediated neural plasticity. The objective of this study was to investigate the plasticity hypothesis in 30...
Therapeutic Advances in Psychopharmacology
2020
Marcos Gómez‐revuelta, María Fernández-Rodríguez, Laura Boada-Antón et al.
Ketamine’s pharmacological profile makes it an interesting and useful drug to challenge treatment-resistant-depression (TRD). Emerging adverse events associated with single-slow-sub-anaesthetic doses for the treatment of depression are common, although generally transient and self-limited. Nevertheless, data on the safety of this practice are scarce. Thus, it seems timely before ketamine is...
Epidemiology and Psychiatric Sciences
2020
Chiara Gastaldon, D. Papola, G. Ostuzzi et al.
Abstract In March 2019, the US Food and Drug Administration (FDA) approved a nasal spray formulation of esketamine for the treatment of resistant depression in adults. Esketamine is the S-enantiomer of ketamine, an FDA-approved anaesthetic, known to cause dissociation and, occasionally, hallucinations. While ketamine has not been approved for depression in the USA or in any other country, it...
Epidemiology and Psychiatric Sciences
2020
Chiara Gastaldon, D. Papola, G. Ostuzzi et al.
Abstract Maju et al. provided clarifications on important and controversial issues related to esketamine clinical trial data, in response to a vivid debate triggered by the marketing authorisation recently granted by this new medicine. In this commentary, we reply to their comments attempting to critically discuss the evidence base needed to obtain regulatory approval.
Advances in pharmacology (San Diego, Calif.)
2020
Lynnette A. Averill, Samar Fouda, James W. Murrough et al.
A paradigm shift in the conceptualization of the neurobiology of depression and the serendipitous discovery of ketamine's rapid-acting antidepressant (RAAD) effects has ushered in a new era of innovative research and novel drug development. Since the initial discovery of ketamine's RAAD effects, multiple studies have supported its short-term efficacy for fast-tracked improvements in...
Therapeutic advances in drug safety
2020
Mohammed S Salahudeen, Cameron M Wright, Gregory M Peterson
This narrative review aims to provide an overview of the current literature on the pharmacology, safety, efficacy and tolerability of intranasal esketamine, the S-enantiomer of ketamine, for the treatment of treatment-resistant depression (TRD). A literature search using Medline, Embase, PsycINFO and Cochrane Central was conducted (January 2000 to July 2019). Product information and...
Therapeutic Advances in Psychopharmacology
2020
Paul Glue, Natalie J. Medlicott, Shona Neehoff et al.
43 citations
Background: Ketamine’s defining side effects are dissociation and increased blood pressure/heart rate. An oral formulation with delayed absorption could minimize these effects. We recently reported safety and tolerability data for an extended release ketamine tablet in healthy volunteers. Methods: To assess safety, tolerability, efficacy, and pharmacokinetics of an extended release oral...
Therapeutic Advances in Psychopharmacology
2020
D. Matveychuk, Rejish K Thomas, Jennifer Swainson et al.
209 citations
Ketamine, a drug introduced in the 1960s as an anesthetic agent and still used for that purpose, has garnered marked interest over the past two decades as an emerging treatment for major depressive disorder. With increasing evidence of its efficacy in treatment-resistant depression and its potential anti-suicidal action, a great deal of investigation has been conducted on elucidating ketamine’s...
Absolute Addiction Psychiatry Review
2020
Mashal Khan, Anil A. Thomas
3 citations
Anabolic-androgenic steroids, inhalants, hallucinogens, dissociative anesthetics and “club drugs” are a heterogeneous group of substances that have considerable potential for misuse and associated morbidity and/or mortality. Steroid use often goes undetected, even by addiction psychiatrists, though significant medical and psychiatric consequences often arise from chronic use. Inhalants, which...
Journal of Affective Disorders
2020
Roman M. Dale, Kelly A. Bryant, Nora Finnegan et al.
17 citations
There are many putative mechanisms by which ketamine has its effect and many unanswered questions about risks and benefits of long-term ketamine therapy. A research imperative is the identification of predictors of response to intravenous ketamine, especially a sustained response to maintenance ketamine. Temperament is an inherited aspect of personality and is a predictive factor for outcome in...
Advances in pharmacology (San Diego, Calif.)
2020
Bashkim Kadriu, Elizabeth D. Ballard, Ioline D. Henter et al.
35 citations
As a field, psychiatry is undergoing an exciting paradigm shift toward early identification and intervention that will likely minimize both the burden associated with severe mental illnesses as well as their duration. In this context, the rapid-acting antidepressant ketamine has revolutionized our understanding of antidepressant response and greatly expanded the pharmacologic armamentarium for...